| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Personalis, Inc. Common Stock$10.54
+0.89 (+9.14%)
F 16Pipeline Score Tools & Services · Commercial
Market Cap
629.88 M
EPS
-0.91
P/E Ratio
-6.62 $
Value Trade
31.35 M
SEC Financials
Q1 2026Dilution Risk
Revenue
15.47 M
R&D Expenses
14.54 M
Operating CF
-22.48 M
Total Assets
325.39 M
Total Liabilities
70.63 M
Equity
254.76 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
233.22 M
Monthly Burn
7.49 M
Runway
29.7 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
3.82 M
52 Week Range
3.09 - 11.50
% held by Insiders
38.51 %
% held by Institutions
62.36 %
Enterprise Value
430.74 M
Total Shares
104.60 M
Short %
19.92 %
Float Shares
65.17 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F16
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 13%
Micro Cap (rank 788 of 905)
Percentile RankPersonalis, Inc. Common Stock has significant pipeline risk (16/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PSNL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Personalis, Inc. Common Stock (PSNL) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
PSNL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PSNL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PSNL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
PSNL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
PSNL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PSNL
Jun 9, 2026Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits
Personalis has announced the launch of CE-IVD marked specimen collection kits aimed at supporting global biopharma initiatives. These kits are designed to enhance the efficiency of specimen collection while ensuring compliance with European regulations. The move is expected to bolster Personalis's position in the biopharma market.
Read more →-PSNL
Jun 2, 2026Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026
Personalis presented findings on early colorectal cancer recurrence detection and the performance of ultrasensitive minimal residual disease (MRD) detection across various tumor types at ASCO 2026. The details of the findings were not disclosed in the article.
Read more →-PSNL
May 26, 2026Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium
Personalis will showcase the capabilities of its NeXT Personal® ultra-sensitive ctDNA data at the ASCO 2026 Annual Meeting. The presentation will include insights from the TRACERx Consortium, highlighting the advancements in cancer detection and monitoring. This event aims to emphasize the importance of ctDNA in personalized medicine.
Read more →-PSNL
May 20, 2026Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring
Personalis has successfully secured a fourth Medicare coverage decision for its NeXT Personal® test, which now includes coverage for pre-surgical treatment monitoring in breast cancer patients. This expansion is expected to enhance patient care by providing more comprehensive monitoring options. The decision reflects growing recognition of the test's value in personalized cancer treatment.
Read more →-PSNL
May 14, 2026Personalis to Participate in Upcoming Investor Events
Personalis is set to participate in upcoming investor events, showcasing its commitment to engaging with stakeholders. The events aim to provide insights into the company's progress and future plans. Further details about the events and their significance were not disclosed in the article.
Read more →-PSNL
May 13, 2026Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors
Personalis has secured Medicare coverage for its NeXT Personal® test, which is designed for immunotherapy monitoring in patients with late-stage solid tumors. This development is expected to improve access to personalized cancer treatment options. The coverage represents a significant advancement in the integration of genomic testing into clinical practice.
Read more →-PSNL
May 7, 2026Personalis Reports First Quarter Results and Recent Highlights
Personalis has reported its first quarter results, but the article provides minimal details on financial performance or significant highlights. The content is primarily focused on privacy aspects, leaving out critical business insights. Stakeholders may find the lack of concrete information concerning.
Read more →-PSNL
Apr 23, 2026Personalis to Announce First Quarter 2026 Financial Results
Personalis, Inc. will announce its first quarter 2026 financial results on May 7, 2026. The company will host a conference call and webcast at 2:00 p.m. PT to discuss these results and recent highlights. Interested parties can access the call via phone or through the company's website.
Read more →-PSNL
Apr 21, 2026Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026
Personalis, Inc. presented promising clinical data at the AACR Annual Meeting, showcasing the effectiveness of their NeXT Personal ultrasensitive ctDNA assay in monitoring treatment responses and tracking therapy resistance. Key findings included high sensitivity in detecting disease and the introduction of a new feature for real-time tracking of mutations. These advancements could significantly enhance cancer management strategies.
Read more →-PSNL
Apr 13, 2026Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026
Personalis, Inc. will present new data on its NeXT Personal ctDNA assay at the AACR Annual Meeting 2026. The highlight includes the Real-Time Variant Tracker, which tracks therapy resistance mutations. Presentations will cover various aspects of colorectal cancer management and the assay's clinical impact, showcasing Personalis' commitment to innovation in cancer care.
Read more →-PSNL
Feb 27, 2026Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
Personalis, Inc. reported significant growth in 2025, highlighted by a 400% increase in clinical volume and new Medicare coverage for breast and lung cancer. The company anticipates a robust financial outlook for 2026, projecting a five-fold increase in clinical revenue. CEO Chris Hall emphasized the importance of their 'Win-in-MRD' strategy and a strong cash position to support expansion efforts.
Read more →-PSNL
Feb 18, 2026Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference
Personalis, Inc. will participate in the TD Cowen 46th Annual Healthcare Conference on March 3, 2026, in Boston. The company's management team will present its advancements in genomics for precision oncology. Personalis aims to enhance cancer management through personalized testing and advanced insights into tumor profiling.
Read more →-PSNL
Feb 2, 2026Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors
Personalis, Inc. has published a study demonstrating the effectiveness of its NeXT Personal test in monitoring immunotherapy responses in advanced cancer patients. The study, conducted by UC San Diego researchers, highlights the assay's ultrasensitive detection of circulating tumor DNA (ctDNA), which can lead to earlier clinical interventions. This research builds on previous findings and emphasizes the need for improved monitoring tools in cancer treatment.
Read more →-PSNL
Jan 29, 2026Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Personalis, Inc. will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026. The event will take place at the Cliff Lodge in Snowbird, Utah. The company focuses on advanced genomics for precision oncology, providing personalized testing and insights for cancer management.
Read more →Competitive Position
How PSNL ranks across every disease it competes inCompetitive Position is a premium feature
See how PSNL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial